Return tothe past: The case for antibody-based therapies in infectious diseases

Clinical Infectious Diseases

Volumn 21, Issue 1, 1995, Pages 150-161

  Arturo, Casadevall ^b   Scharff, Matthew D ^a,b  

^a Division of Infectious Diseases   (United States)

^b ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; ANTIINFECTIVE AGENT; ANTISERUM; DIGOXIN; DIPHTHERIA TOXIN; EPITOPE; IMMUNOGLOBULIN; METICILLIN; MONOCLONAL ANTIBODY; PENICILLIN G; POLYCLONAL ANTIBODY; POLYSACCHARIDE; PROTEINASE; SULFANILAMIDE; SULFONAMIDE; TETANUS TOXIN; TUMOR NECROSIS FACTOR;

ALLERGIC REACTION; ANTIBIOTIC RESISTANCE; ANTIBODY RESPONSE; ASEPTIC MENINGITIS; AUTOIMMUNITY; BACTERIAL INFECTION; BLOOD BRAIN BARRIER; CLINICAL TRIAL; DRUG POTENTIATION; DRUG THERAPY; HUMAN; INFECTION; INTRAVENOUS DRUG ADMINISTRATION; KIDNEY FAILURE; MORTALITY; NONHUMAN; OPPORTUNISTIC INFECTION; PRIORITY JOURNAL; REVIEW; SEROTYPE; SERUM SICKNESS; VIRUS INFECTION; VIRUS NEUTRALIZATION;

ANTIBIOTICS; ANTIBODIES; ANTIBODIES, MONOCLONAL; BACTERIAL INFECTIONS; HUMAN; IMMUNOTHERAPY, ADOPTIVE; SUPPORT, NON-U.S. GOV'T; SUPPORT, U.S. GOV'T, P.H.S.; VIRUS DISEASES;

EID: 0029032565     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/clinids/21.1.150     Document Type: Article

References (181)

1. Armstrong D. History of opportunistic infection in the immunocompromised host. Clin Infect Dis 1993; 17 (suppl 2);S318-21.
2. Sepkowitz KA, Telzak EE, Recalde S, Armstrong D, New York City Area Tuberculosis Working Group. Trends in the susceptibility of tuberculosis in New York City, 1987-1991. Clin Infect Dis 1994; 18:755-9.
3. Hook EW III. Management of syphilis in human immunodeficiency virus-infected patients [editorial]. Am J Med 1992;93:477-9.
4. Schlaes DM, Binczewski B, Rice LB. Emerging antimicrobial resistance and the immunocompromised host. Clin Infect Dis 1993; 17 (suppl 2):S527-36.
5. Boyle JF, Soumakis SA, Rendo A, et al. Epidemiologic analysis and genotypic characterization of a nosocomial outbreak of vancomycin-resistant enterococci. J Clin Microbiol 1993;31:1280-5.
6. Cameron ML, Schell WA, Bruch S, Bartlett JA, Waskin HA, Perfect JR. Correlation of in vitro fluconazole resistance of Candida isolates in relation to therapy and symptoms of individuals seropositive for human immunodeficiency virus type I. Antimicrob Agents Chemother 1993; 37:2449-53.
7. Casadevall A, Scharff MD. Serum therapy revisited: animal models of infection and development of passive antibody therapy. Antimicrob Agents Chemother 1994;38:1695-702.
8. Alexander HE. Treatment of Haemophilus influenzae infections and of meningococcic and pneumococcic meningitis. Am J Dis Child 1943; 66:172-87.
9. Alexander HE. Experimental basis for treatment of Haemophilus influenzae infections. Am J Dis Child 1943;66:160-71.
10. Fothergill LRD. Haemophilus influenzae (Pfeiffer bacillus) meningitis and its specific treatment. New Engl J Med 1937;216:587-90.
11. Wesselhoeft C. Treatment of scarlet fever and diphtheria. Med Clin North Am 1936;19:1389-407.
12. Wadsworth AB. The hemolytic streptococci and antistreptococcus serum in scarlet fever. Am J Public Health 1929; 19:1287-302.
13. Blake FG, Trask JD. Therapeutic value of scarlatinal antitoxin. NY State J Med 1925;25:1093-9.
14. Birkhaug KE. Studies in scarlet fever. II. Studies on the use of convalescent scarlet fever serum and Dochez' scarlatinal antistreptococcic serum for the treatment of scarlet fever. Bull Johns Hopkins Hosp 1925;36:134-71.
15. Birkhaug KE. The etiology of erysipelas. Arch Pathol 1928;6:441-75.
16. Frank WP, Patton EF, Hamilton PM. Treatment of whooping cough bronchopneumonia. J Pediatr 1942;20:720-2.
17. Rascoff H, Nussbaum S. Therapeutic procedures for scarlet fever: comparative studies. Am J Dis Child 1940;60:552-61.
18. McGuinness AC, Armstrong JG, Felton IIM. Hyperimmune whooping cough serum: further studies. J Pediatr 1944;24:249-58.
19. Scheinblum IE, Bullowa JGM. The treatment of pertussis with lyophile hyperimmune human pertussis serum. J Pediatr 1944;25:49-55.
20. Lapin JH. Serum in the prophylaxis of contacts and the treatment of whooping cough. J Pediatr 1945;26:555-9.
21. Lucchesi PF, Gildersleeve N. The treatment of anthrax. JAMA 1941; 116:1506-8.
22. Tacket CO, Shandera WX, Mann JM, Hargrett NT, Blake PA. F.quine antitoxin use and other factors that predict outcome in type A food-borne botulism. Am J Med 1984;76:794-8.
23. Rackemann FM. Allergy: serum reactions, with particular reference to the prevention and treatment of tetanus. N Engl J Med 1942; 226: 726-33.
24. Spaeth R. Therapy of tetanus. A study of two hundred and seventy-six cases. Arch Intern Med 1941;68:1133-60.
25. Carpenter CM, Boak RA. The treatment of human brucellosis. A review of current therapeutic methods. Medicine (Baltimore) 1936; 15: 103-28.
26. Graham D. Some points in the diagnosis and treatment of dysentery occurring in the British Salonika force. Lancet 1918;1:51-5.
27. Manson-Bahr P. The dysenteric disorders. In: The diagnosis and treatment of dysentery, sprue, colitis, and other diarrhoeas in general practice. Baltimore: Williams & Wilkins, 1939:97-106.
28. Foshay L. Tularemia: a summary of certain aspects of the disease including methods for early diagnosis and the results of serum treatment in 600 patients. Medicine (Baltimore) 1940;19:1-83.
29. Gallagher JR. Use of convalescent measles serum to control measles in a preparatory school. Am J Public Health 1935;25:595-8.
30. Zingher A. Convalescent whole blood, plasma and serum in prophylaxis of measles. JAMA 1924;82:1180-7.
31. Park WII, Freeman RG. The prophylactic use of measles convalescent serum. JAMA 1926;87:556-61.
32. Park WII. Therapeutic use of antipoliomyelitis serum in preparalytic cases of poliomyelitis. JAMA 1932;99:1050-3.
33. Lewis JM, Barenberg LH. The use of convalescent serum in the treatment of measles, chicken-pox, mumps and whooping cough, including the prophylactic value of parental blood. NY State J Med 1933;33:97-9.
34. Wesselhoeft C. Mumps. New Engl J Med 1942;226:530-4.
35. Weech AA. The prophylaxis of varicella with convalescents’ serum. JAMA 1924;82:1245-6.
36. Finland M, Brown JW. Specific treatment of pneumococcus Type 1 pneumonia. Including the use of horse and rabbit antipneumococcus serums and sulphanilamide. Am J Med Sci 1939;197:151-68.
37. Symmers D, Lewis KM. The antitoxin treatment of erysipelas: further observations. JAMA 1932;99:1082-3.
38. Flexner S. The results of the serum treatment in thirteen hundred cases of epidemic meningitis. J Exp Med 1913; 17:553-76.
39. Lucchesi PF, Bowman JE. Antitoxin versus no antitoxin in scarlet fever. JAMA 1934;103:1049-51.
40. McCloskey RV. Corynebacterium diphtheriae (diphtheria). In: Mandell GL, Douglas RG Jr, Bennett JE, eds. Principles and practice of infectious diseases. 2nd ed. New York: John Wiley & Sons, 1985: 1171-4.
41. Fothergill LD. Some recent advances in vaccines and serums: a review. Med Clin North Am 1936; 19:1409-38.
42. Christian HA. The principles and practice of medicine. 15th ed. New York: Appleton-Century Company, 1944.
43. Watson DA, Musher DM, Jacobson JW, Verhoef J. A brief history of the pneumococcus in biomedical research: a panoply of scientific discovery. Clin Infect Dis 1993;17:913-24.
44. Kolmer JA. Progress in chemotherapy of bacterial and other diseases; with special reference to the prontosils, sulfanilamide and sulfapyri-dine. Arch Intern Med 1940;65:671-743.
45. Feinberg SM. The therapy of (horse) serum reactions: general rules in the administration of therapeutic serums. JAMA 1936;107:1717-9.
46. Felton LD. The units of protective antibody in anti-pneumococcus serum and antibody solution. J Infect Dis 1928;43:531-42.
47. Finland M. The use of serum, sulfanilamide, and sulfapyridine in the treatment of pneumococcic infections. Med Clin North Am 1939; 23:1205-19.
48. Pepper DS, Flippin HF, Schwartz L, Lockwood JS. The results of sulfapyridine therapy in 400 cases of typed pneumococcic pneumonia. Am J Med Sci 1939;198:22-35.
49. Nelson J, Rinzler H, Kelsey MP. Sulfanilamide treatment of erysipelas. JAMA 1939;112:1044-5.
50. Waghelstein JM. Sulfanilamide in the treatment of 106 patients with meningococcic infections. JAMA 1938;111:2172-4.
51. Dowling HF, Abemethy TJ. The treatment of pneumococcus pneumonia: a comparison of the results obtained with specific serum and with sulfapyridine. Am J Med Sci 1940;199:55-62.
52. Kepi M, Gunn FD. Sulfapyridine and serum therapy in experimental lobar pneumonia of rats. Proc Soc Exp Biol Med 1939;40:529-32.
53. Gross P, Cooper FB. P-aminobenzenesulfonamide and antipneumococcal serum therapy in type I pneumococcal infections of rats. Proc Soc Exp Biol Med 1937;36:535-40.
54. MacLeod CM. Chemotherapy of pneumococcic pneumonia. Clinical lecture al St. Louis session. JAMA 1939; 113:1405-10.
55. Powell HM, Jamieson WA. Combined therapy of pneumococcic rat infections with rabbit antipneumococcic serum and sulfapyridine (2-sulfa-nilyl aminopyridine). J Immunol 1939;36:459-65.
56. Waisbren BA. The treatment of bacterial infections with the combination of antibiotics and gamma globulin. Antibiot Chemother 1957; 7: 322- 33.
57. Branham SE. Sulphanilamide, serum, and combined drug and serum therapy in experimental meningococcus and pneumococcus infections in mice. Public Health Rep 1937;52:685-95.
58. Tunnicliff R. The action of prontosil-soluble and sulfanilamide on the phagocytic activity of leukocytes and on the dissociation of streptococci. J Infect Dis 1939;64:59-65.
59. Osgood EE, Powell HM. Failure of sulfanilamide to inactivate preformed hemotoxins, diphtheric toxin, or tctanal toxin. Proc Soc Exp Biol Med 1938;39:37-40.
60. Sako W, Dwan PF, Platou ES. Sulfanilamide and serum in the treatment and prophylaxis of scarlet fever. JAMA 1938; 111:995-7.
61. Finland M, Spring WC, Lowell FC, Brown JW. Specific serotherapy and chemotherapy of the pneumococcus pneumonias. Ann Intern Med 1939;17:1816-29.
62. Finland M, Brown JW, Rauh AE. Treatment of pneumococci meningitis: a study of ten cases treated with sulfanilamide alone or in various combinations with antipneumococcic serum and complement, including six recoveries. N Engl J Med 1938;218:1033-44.
63. Schwentker FF, Gelman S, Long PH. The treatment of meningococcic meningitis with sulfanilamide: preliminary report. JAMA 1937;108: 1407-8.
64. Banks HS. Serum and sulphanilamide in acute meningococcal meningitis: a preliminary survey based on 113 cases. Lancet 1938;2:7-13.
65. Bussel JB, Cunningham-Rundles C. Intravenous usage of gammaglobulin: humoral immunodeficiency, immune thrombocytopenic purpura, and newer indications. Cancer Invest 1985;3:361-6.
66. Moderator: Stiehm ER, Discussants: Ashida E, Kim KS, Winston DJ, Hass A, Gale RP. Intravenous immunoglobulins as therapeutic agents. Ann Intern Med 1987; 107:367-82.
67. Pennington JE. Newer uses of intravenous immunoglobulins as anti-infective agents. Antimicrob Agents Chemother 1990;34:1463-6.
68. Yap PL. Prevention of infection in patients with B cell defects: focus on intravenous immunoglobulin. Clin Infect Dis 1993; 17 (suppl 2): S372-5.
69. Watt CH. Poisonous snakebite treatment in the United States. JAMA 1978;240:654-6.
70. Rappolt RT, Quinn H, Curtis L, Minion SA, Murphy JB. Medical toxicologist’s notebook: snakebite treatment and international antivenin index. Clinical Toxicology 1978;13:409-38.
71. Conti DJ, Freed BM, Gruber SA, Lempert N. Prophylaxis of primary cytomegalovirus disease in renal transplant recipients: a trial of ganciclovir vs. immunoglobulin. Arch Surg 1994;129:443-7.
72. Reed EC, Bowden RA, Dandliker PS, Lilleby KE, Meyers JD. Treatment of cytomegalovirus pneumonia wilh ganciclovir and intravenous cytomegalovirus immunoglobulin in patients with bone marrow transplants. Ann Intern Med 1988;109:783-8.
73. Bames GL, Doyle LW, Hewson PH, et al. A randomised trial of oral gammaglobulin in low-birth-weight infants infected with rotavirus. Lancet 1982;1:1371-3.
74. Clayton AJ. Lassa immune serum. Bull WHO 1977;55:435-9.
75. Brunell PA, Gershon AA, Hughes WT, Riley HD, Smith J. Prevention of varicella in high risk children: a collaborative study. Pediatrics 1972;50:718-22.
76. Wilfert CM, Buckley RH, Mohanakumar T, et al. Persistent and fatal central-nervous system echovirus infections in patients with agammaglobulinemia. New Engl J Med 1977;296:1485-9.
77. Bodensteiner JB, Morris HH, Howell JT, Schochet SS. Chronic ECHO type 5 vims meningoencephalitis in X-linked hypogammaglobulinemia: treatment with immune plasma. Neurology 1979;29:815-9.
78. Frickhofen N, Abkowitz JL, Safford M, et al. Persistent B19 parvovirus infection in patients infected with human immunodeficiency virus type 1 (HIV-1): a treatable cause of anemia in AIDS. Ann Intern Med 1990;113:926-33.
79. Mofenson LM, Moye J, Korelitz J, Bethel J, Hirschhom R, Nugent R. Crossover of placebo patients to intravenous immunoglobulin confirms efficacy for prophylaxis of bacterial infections and reduction of hospitalizations in human immunodeficiency virus-infected children. Pediatr Infect Dis J 1994; 13:477-84.
80. Yap PL. Does intravenous immune globulin have a role in HIV-infected patients? Clin Exp Immunol 1994;97 (suppl 1):59-67.
81. The National Institute of Child Health and Human Development Intravenous Immunoglobulin Study Group. Intravenous immune globulin for the prevention of bacterial infections in children with symptomatic human immunodeficiency virus infection. N Engl J Med 1991; 325: 73-80.
82. The Intravenous Immunoglobulin Collaborative Study Group. Prophylactic intravenous administration of standard immune globulin as compared with core-lipopolysaccharide immune globulin in patients at high risk of postsurgical infection. New Engl J Med 1992;327:234-40.
83. Stratta RJ, Schaefer MS, Cushing KA, et al. A randomized prospective trial of acyclovir and immune globulin prophylaxis in liver transplant recipients receiving OKT3 therapy. Arch Surg 1992;127:55-64.
84. Chirico G, Rondini G, Plebani A, Chiara A, Massa M, Ugazio AG. Intravenous gammaglobulin therapy for prophylaxis of infection in high-risk neonates. J Pediatr 1987;110:437-42.
85. Baker CJ, Melish ME, Hall RT, Casto DT, Vasan U, Givner LB, Multicenter Group for the Study of Immune Globulin in Neonates. Intravenous immune globulin for the prevention of nosocomial infection in low-birth-weight neonates. New Engl J Med 1992;327:213-9.
86. Hill HR. Intravenous immunoglobulin use in the neonate: role in prophylaxis and therapy of infection. Pediatr Infect Dis J 1993; 12:549-59.
87. Zanetti G, Glauser MP, Baumgartner J-D. Use of immunoglobulins in prevention and treatment of infection in critically ill patients: review and critique. Rev Infect Dis 1991;13:985-92.
88. Stiehm ER. New uses for intravenous immune globulin [editorial]. New Engl J Med 1991;325:123-5.
89. Siber GR. Immune globulin to prevent nosocomial infections [editorial]. New Engl J Med 1992;327:269-71.
90. Whittle MJ. Rhesus haemolytic disease. Arch Dis Child 1992;67:65-8.
91. Cosimi AB. The clinical value of antilymphocyte antibodies. Transplant Proc 1981;13:462-8.
92. Ortho Multicenter Transplant Study Group. A randomized clinical trial of OKT3 monoclonal antibody for acute rejection of cadaveric renal transplants. New Engl J Med 1985;313:337-42.
93. Smith TW, Butler VP, Haber E, et al. Treatment of life-threatening digitalis intoxication with digoxin-specific Fab antibody fragments: experience in 26 cases. New Engl J Med 1982;307:1357-62.
94. Weisman LE, Cruess DF, Fischer GW. Opsonic activity of commercially available standard intravenous immunoglobulin preparations. Pediatr Infect Dis J 1994; 13:1122-5.
95. Slade HB. Human immunoglobulins for intravenous use and hepatitis C viral transmission. Clin Diagn Lab Immunol 1994;1:613-9.
96. Kohler G, Milstein C. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 1975;256:495-7.
97. Wright A, Shin S-U, Morrison SL. Genetically engineered antibodies: progress and prospects. Crit Rev Immunol 1992; 12:125-68.
98. LoBuglio AF, Wheeler RH, Trang J, et al. Mouse/human chimeric monoclonal antibody in man: kinetics and immune response. Proc Natl Acad Sci USA 1989;86:4220-4.
99. Warren HS, Danner RL, Munford RS, Anti-endotoxin monoclonal antibodies. N Engl J Med 1992;326:1153-7.
100. Luce JM. Introduction of new technology into critical care practice: a history of HA-1A human monoclonal antibody against endotoxin. Crit Care Med 1993;21:1233-41.
101. Klemperer G, Klemperer F. Versuche fiber immunisirung und heilung bei der pneumokokkeninfektion. Berl Klin Wochenschr 1891; 28: 833-5.
102. Dochez AR, Gillespie LJ. A biologic classification of pneumococci by means of immunity reactions. JAMA 1913;61:727-32.
103. Neufeld F, Haendel. Weitere Untersuchungen uber Pneumokokken-Heil-sera. Arb a d k Gesundheitsamte 1910;34:293-304.
104. Bullowa JGM. The reliability of sputum typing and its relation to serum therapy. JAMA 1935;105:1512-8.
105. Branham SE. The meningococcus (Neisseria intracellularis). Bacteriol Rev 1940;4:59-96.
106. Branham SE. Serums, antitoxin, and drugs in the treatment of meningococcus meningitis. Public Health Rep 1938; 53:645-51.
107. Bullowa JGM. The management of the pneumonias. New York: Oxford University Press, 1937.
108. Heinzel FP. Antibodies. In: Mandell GL, Bennett JE, Dolin R, eds. Principles and practice of infectious diseases. New York: Churchill Livingstone, 1995:36-57.
109. Oishi K, Sonoda F, Iwagaki A, et al. Therapeutic effects of a human antiflagella monoclonal antibody in a neutropenic murine model of Pseudomonas aeruginosa pneumonia. Antimicrob Agents Chemother 1993;37:164-70.
110. Halstead SB, Immune enhancement of viral infection. Prog Allergy 1982;31:301-64.
111. Waldmann TA, Strober W. Metabolism of immunoglobulins. Prog Allergy 1969;14:1-110.
112. Zuckier LS, Rodriguez LD, Scharff MD. Immunologic and pharmacologic concepts of monoclonal antibodies. Semin Nucl Med 1989; 19:166-86.
113. Virella G, Nunes MAS, Tamagnini G. Placental transfer of human IgG subclasses. Clin Exp Immunol 1972;10:475-8.
114. Borowitz SM, Saulsbury FT. Treatment of chronic cryptosporidial infection with orally administered human serum immune globulin. J Pediatr 1991;119:593-5.
115. Hoyne AL. Intravenous treatment of meningococcic meningitis with meningococcus antitoxin. JAMA 1936;107:478-81.
116. Triguero D, Buciak JB, Yang J, Pardridge WM. Blood-brain barrier transport of cationized immunoglobulin G: enhanced delivery compared to native protein. Proc Natl Acad Sci USA 1989;86:4761-5.
117. Friden PM, Walus LR, Musso GF, Taylor MA, Malfroy B, Starzyk RM. Anti-transferrin receptor antibody and antibody-drug conjugates cross the blood-brain barrier. Proc Natl Acad Sci USA 1991;88:4771-5.
118. Pasatiempo AMG, Kroser JA, Rudnick M, Hoffrnan BI. Acute renal failure after intravenous immunoglobulin therapy. J Rheumatol 1994; 21:347-9.
119. Sekul EA, Cupler EJ, Dalakas MC. Aseptic meningitis associated with high-dose intravenous immunoglobulin therapy: frequency and risk factors. Ann Intern Med 1994;121:259-62.
120. Wolff SN, Fay JW, Herzig RH, et al. High-dose weekly intravenous immunoglobulin to prevent infections in patients undergoing autologous bone marrow transplantation or severe myelosuppressive therapy: a study of the American Bone Marrow Transplant Group. Ann Intern Med 1993;118:937-42.
121. Dalakas MC. High-dose intravenous immunoglobulin and serum viscosity: risk of precipitating thromboembolic events. Neurology 1994; 44:223-6.
122. Lang AB, Cryz SJ, Schurch U, Ganss MT, Bruderer U. Immunotherapy with human monoclonal antibodies: fragment A specificity of polyclonal and monoclonal antibodies is crucial for full protection against tetanus toxin. J Immunol 1993;151:466-72.
123. Greenman RL, Schein RMH, Martin MA, et al. A controlled clinical trial of E5 murine monoclonal IgM antibody to endotoxin in the treatment of gram-negative sepsis. JAMA 1991;266:1097-102.
124. Schroff RW, Foon KA, Beatty SM, Oldham RK, Morgan AC. Human anti-murine immunoglobulin responses in patients receiving monoclonal antibody therapy. Cancer Res 1985;45:879-85.
125. van der Lubbe PA, Reiter C, Breedveld FC, et al. Chimeric CD4 monoclonal antibody CM-T412 as a therapeutic approach to rheumatoid arthritis. Arthritis Rheum 1993;36:1375-9.
126. Lazarovits AI, Rochon J, Banks L, et al. Human mouse chimeric CD7 monoclonal antibody (SDZCHH380) for the prophylaxis of kidney transplant rejection. J Immunol 1993;150:5163 - 74.
127. Issacs JD, Watts RA, Hazleman BL, et al. Humanised monoclonal antibody therapy for rheumatoid arthritis. Lancet 1992;340:748-52.
128. Hale G, Dyer MJS, Clark MR, et al. Remission induction in non-Hodgkin lymphoma with reshaped human monoclonal antibody CAMPATH-1H. Lancet 1988;2:1394-9.
129. Sadziene A, Rosa PA, Thompson PA, Hogan DM, Barbour AG. Antibody-resistant mutants of Borrelia burgdorferi: in vitro selection and characterization. J Exp Med 1992;176:799-809.
130. Halter R, Pohlner J, Meyer TF. Mosaic-like organization of IgA protease genes in Neisseria gonorrhoeae generated by horizontal genetic exchange in vivo. EMBO J 1989;8:2737-44.
131. Weeks JC, Tiemey MR, Weinstein MC. Cost effectiveness of prophylactic intravenous immune globulin in chronic lymphocytic leukemia. New Engl J Med 1991;325:81-6.
132. Graybill JR, Hague M, Drutz DJ. Passive immunization in murine cryptococcosis. Sabouraudia 1981;19:237-44.
133. Gadebusch HH. Passive immunization against Cryptococcus neoformans. Proc Soc Exp Biol Med 1958;98:611-4.
134. Dromer F, Charreire J, Contrepois A, Carbon C, Yeni P. Protection of mice against experimental cryptococcosis by anti-Cryptococcus neoformans monoclonal antibody. Infect Immun 1987;55:749-52.
135. Sanford JE, Lupan DM, Schlageter AM, Kozel TR. Passive immunization against Cryptococcus neoformans with an isotype-switch family of monoclonal antibodies reactive with cryptococcal polysaccharide. Infect Immun 1990;58:1919-23.
136. Mukheijee J, Scharff MD, Casadevall A. Protective murine monoclonal antibodies to Cryptococcus neoformans. Infect Immun 1992; 60: 4534-41.
137. Gordon MA, Lapa E. Serum protein enhancement of antibiotic therapy in cryptococcosis. J Infect Dis 1964; 114:373-8.
138. Dromer F, Charreire J. Improved amphotericin B activity by a monoclonal unti-Cryptococcus neoformans antibody: study during murine cryptococcosis and mechanisms of action. J Infect Dis 1991; 163:1114-20.
139. Mukheijee J, Zuckier LS, Scharff MD, Casadevall A. Therapeutic efficacy of monoclonal antibodies to Cryptococcus neoformans gluc-uronoxylomannan alone and in combination with Amphotericin B. Antimicrob Agents Chemother 1994;38:580-7.
140. Yuan R, Casadevall A, Spira G, Scharff MD. Isotype switching from IgG3 to IgGl converts a non-protective murine antibody to C. neoformans into a protective antibody. J Immunol 1995 (in press).
141. Mukheijee J, Nussbaum G, Scharff MD, Casadevall A. Protective and nonprotective monoclonal antibodies to Cryptococcus neoformans originating from one B cell. J Exp Med 1995 (in press).
142. Mineo JR, Khan IA, Kasper LH. Toxoplasma gondii: a monoclonal antibody that inhibits intracellular replication. Exp Parasitol 1994; 79: 351-61.
143. Mazanec MB, Kaetzel CS, Lamm ME, Fletcher D, Nedrud JG. Intracellular neutralization of virus by immunoglobulin A antibodies. Proc Natl Acad Sci USA 1992;89:6901-5.
144. Yanase K, Smith RM, Cizman B, et al. A subgroup of murine monoclonal anti-deoxyribonucleic acid antibodies traverse the cytoplasm and enter the nucleus in a time- and temperature-dependent manner. Lab Invest 1994;71:52-60.
145. Gigliotti F, Hughes WT. Passive immunoprophylaxis with specific monoclonal antibody confers partial protection against Pneumocystis carinii pneumonitis in animal models. J Clin Invest 1988;81:1666-8.
146. Doyle PS, Crabb J, Petersen C. AnXi-Cryptosporidium parvum antibodies inhibit infectivity in vitro and in vivo. Infect Immun 1993; 61: 4079-84.
147. Dromer F, Salamero J, Contrepois A, Carbon C, Yeni P. Production, characterization, and antibody specificity of a mouse monoclonal antibody reactive with Cryptococcus neoformans capsular polysaccharide. Infect Immun 1987;55:742-8.
148. Matthews RC, Bumie JP, Howat D, Rowland T, Walton F. Autoantibody to heat-shock protein 90 can mediate protection against systemic can-didosis. Immunology 1991;74:20-4.
149. Erlich KS, Dix RD, Mills J. Prevention and treatment of experimental herpes simplex virus encephalitis with human immune serum globulin. Antimicrob Agents Chemother 1987;31:1006-9.
150. Aulitzky WE, Schulz TF, Tilg H, et al. Human monoclonal antibodies neutralizing cytomegalovirus (CMV) for prophylaxis of CMV disease: report of a phase I trial in bone marrow transplant recipients. J Infect Dis 1991;163:1344-7.
151. Pennington JE, Small GJ, Lostrom ME, Pier GB. Polyclonal and monoclonal antibody therapy for experimental Pseudomonas aeruginosa pneumonia. Infect Immun 1986;54:239-44.
152. Pier GB, Thomas D, Small G, Siadak A, Zweerink H. In vitro and in vivo activity of polyclonal and monoclonal human immunoglobulins G, M, and A against Pseudomonas aeruginosa lipopolysaccharide. Infect Immun 1989;57:174-9.
153. Austrian R. Confronting drug-resistant pneumococci [editorial], Ann Intern Med 1994;121:807-9.
154. Correa AG, Baker CJ, Schutze GE, Edwards MS. Immunoglobulin G enhances C3 degradation on coagulase-negative staphylococci. Infect Immun 1994;62:2362-6.
155. Ramisse F, Szatanik M, Binder P, Alonso J-M. Passive local immunotherapy of experimental staphylococcal pneumonia with human intravenous immunoglobulin. J Infect Dis 1993; 168:1030-3.
156. Arduino RC, Murray BE, Rakita RM. Roles of antibodies and complement in phagocytic killing of enterococci. Infect Immun 1994; 62: 987-93.
157. Ziegler EJ, McCutchan JA, Fierer J, et al. Treatment of gram-negative bacteremia and shock with human antiserum to a mutant Escherichia coli. N Engl J Med 1982;307:1225-30.
158. Harkonen S, Scannon P, Mischak RP, et al. Phase I study of a murine monoclonal anti-lipid A antibody in bacteremic and nonbacteremic patients. Antimicrob Agents Chemother 1988;32:710-6.
159. Pennington JE. Therapy with antibody to tumor necrosis factor in sepsis. Clin Infect Dis 1993; 17 (suppl 2):S515-9.
160. Cross AS, Opal SM, Palardy JE, Bodmer MW, Sadoff JC. The efficacy of combination immunotherapy in experimental Pseudomonas sepsis. J Infect Dis 1993;167:112-8.
161. See RH, Chow AW. Microbiology of toxic shock syndrome: overview. Rev Infect Dis 1989; 1l(suppl l):S55-60.
162. Talkington DF, Schwartz B, Black CM, et al. Association of phenotypic and genotypic characteristics of invasive Streptococcus pyogenes isolates with clinical components of streptococcal toxic shock syndrome. Infect Immun 1993;61:3369-74.
163. Barry W, Hudgins L, Donta ST, Pesanti EL. Intravenous immunoglobulin therapy for toxic shock syndrome. JAMA 1992;267:3315-6.
164. Zebedee SL, Barbas CF III, Horn YL, et al. Human combinatorial antibody libraries to hepatitis B surface antigen. Proc Natl Acad Sci USA 1992;89:3175-9.
165. Zolla-Pazner S, Gomy MK. Passive immunization for the prevention and treatment of HIV infection. AIDS 1992;6:1235-47.
166. Barbas CF III, Crowe JE, Cababa D, et al. Human monoclonal Fab fragments derived from a combinatorial library bind to respiratory syncytial virus F glycoprotein and neutralize infectivity. Proc Natl Acad Sci USA 1992;89:10164-8.
167. Kim KS. Efficacy of human immunoglobulin and penicillin G in treatment of experimental group B streptococcal infection. Pediatr Res 1987; 21:289-92.
168. Branham SE. Protection of mice against meningococcus infection by polyvalent antimeningococcic serum. Public Health Rep 1935; 50: 768-78.
169. Sonea S, Barduas A, Frapier A. Combined protective action of human gamma globulin and antibiotics when administered simultaneously in experimental staphylococcal infections. Rev Can Biol 1958; 17:110-5.
170. Fisher MW. Synergism between human gamma globulin and chloroam-phenicol in the treatment of experimental bacterial infections. Antibiot Chemother 1957;7:315-21.
171. Loewenthal L, Berlin MD. Combined serum and sulphanilamide in the treatment of streptococcal infections in mice. Lancet 1939;1:197-9.
172. Young LS, Gascon R, Alam S, Bermudez LE. Monoclonal antibodies for treatment of gram-negative infections. Rev Infect Dis 1989; 11 (suppl 7):S1564-71.
173. Romulo RLC, Palardy JE, Opal SM. Efficacy of anti-endotoxin monoclonal antibody E5 alone or in combination with ciprofloxacin in neutropenic rats with Pseudomonas sepsis. J Infect Dis 1993; 167:126-30.
174. Fallon PG, Smith P, Nicholls T, Modha J, Doenhoff MJ. Praziquantel-induced exposure of Schistosoma mansoni alkaline phosphatase: drug-antibody synergy which acts preferentially against female worms. Parasite Immunol 1994;16:529-35.
175. Neely AN, Holder IA. Effects of immunoglobulin G and low-dose amphotericin B on Candida albicans infections in burned mice. Antimicrob Agents Chemother 1992;36:643-6.
176. Feldmesser M, Mukhetjee J, Casadevall A. Combination of 5-flucytosine and capsule-binding monoclonal antibody in therapy of Cryptococcus neoformans infection. Proceedings of the Second National Conference on Human Retroviruses and Related Infections (Washington, DC), 1995.
177. Jahrling PB, Peters CJ, Stephen EL. Enhanced treatment of Lassa fever by immune plasma combined with ribavirin in cynomolgus monkeys. J Infect Dis 1984; 149:420-7.
178. Wilson EJ, Medearis DN, Hansen LA, Rubin RH. 9-(l-3-Dihydroxy-2-Propoxymethyl) guanine prevents death but not immunity in murine cytomegalovirus-infected normal and immunosuppressed BALB/c mice. Antimicrob Agents Chemother 1987;31:1017-20.
179. Cho CT, Feng KK. Combined effects of acycloguanosine and humoral antibodies in experimental encephalitis due to Herpesvirus hominis. J Infect Dis 1980; 142:451.
180. Cho CT, Feng KK, Brahmacupta N. Synergistic antiviral effects of adenine arabinoside and humoral antibodies in experimental encephalitis due to Herpesvirus hominis. J Infect Dis 1976; 133:157-67.
181. Anonymous. Unequalled but unobtainable [editorial]. Lancet 1943; 1:403-4.